Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 5, 2021
BioMarin Also Pausing Further Enrollment of Additional Participants Outside the U.S. in Phearless Phase 1/2 StudyBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the U.S Food and Drug Administration (FDA) placed a clinical hold on the BMN 307 Phearless Phase 1/2 study. The Phearless study is...
-
Aug 27, 2021Achondroplasia is the Most Common Cause of Dwarfism
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Commission (EC) has granted marketing authorization for VOXZOGO® (vosoritide), a once daily injection to treat...
-
Aug 25, 2021- Morgan Stanley 19th Annual Global Healthcare Conference on September 10 at 1:15pm ET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in three upcoming virtual investor conferences. An audio webcast of the presentations will be available...
-
Jul 28, 2021- Total Revenues Grew 17% in the Second Quarter 2021 Compared to Second Quarter 2020
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2021 2020 % Change 2021 2020 % Change Total Revenues $ 501.7
-
Jul 21, 2021Sustained Clinical Hemostatic Efficacy Observed in Study Participants with Longest Duration of Clinical Experience for any Gene Therapy in Hemophilia A
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today new data for valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A, from its...
-
Jul 19, 2021Largest Gene Therapy Study in Hemophilia A Demonstrates Superiority in Key Clinical Efficacy Endpoints Compared to Baseline Factor VIII Prophylactic Therapy
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced new data for valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, in its...
-
Jul 15, 2021Potential 1st Gene Therapy in Europe for Treatment of Hemophilia A
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Medicines Agency (EMA) validated the Company's Marketing Authorization Application (MAA) for its investigational gene...
-
Jul 14, 2021
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday,...
-
Jul 2, 2021Findings to be Presented from Ongoing Studies of Valoctocogene Roxaparvovec Represent Largest and Longest Development Program for any Gene Therapy in Hemophilia A
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced three oral presentations and nine poster presentations related to valoctocogene roxaparvovec, an investigational gene therapy for the...
-
Jun 28, 2021Valoctocogene Roxaparvovec MAA Granted Request for Accelerated Assessment
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company resubmitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its investigational...
-
Jun 25, 2021European Commission Decision expected Q3 2021
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for...
-
Jun 15, 2021
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in the BofA Securities 2021 Napa Biopharma Conference on June 16, 2021 at 3:30pm ET. An audio webcast...
-
May 27, 2021- Jefferies Virtual Healthcare Conference on June 3 at 1:00pm ET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences. An audio webcast of the presentations will be available live. You...
-
May 24, 2021MAA Resubmission on Track for June 2021
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Medicines Agency (EMA) has granted its request for accelerated assessment of valoctocogene roxaparvovec, for adults...
-
May 19, 2021All Study Participants in 6e13 vg/kg and 4e13 vg/kg Dose Cohorts Remain off Factor VIII Prophylactic Therapy
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results from an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene...
-
May 18, 2021-- RBC Capital Markets Global Healthcare Conference on May 19 at 11:30am ET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences. An audio webcast of the presentations will be available live. You...
-
May 12, 2021Research Findings are Part of the Largest and Longest Development Program for any Gene Therapy in Hemophilia A and Advance the Scientific Understanding of AAV5 Gene Therapy
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced three oral and three poster presentations on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults...
-
May 3, 2021- 7th Annual Truist Securities Life Sciences Summit on May 4 at 1:50pm ET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences. An audio webcast of the presentations will be available live. You...
-
Apr 29, 2021- Full-year 2021 Financial Guidance Reaffirmed
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2021 2020 % Change Total Revenues $ 486.0 $ 502.1 (3) % Net Product Revenues...
-
Apr 28, 2021The collaboration leverages technologies intended to target gene expression to specific cells within the central nervous system
The Allen Institute and BioMarin Pharmaceutical Inc. announced a collaboration today that will use technologies developed at the Allen Institute to create new gene therapies aimed at rare genetic...
-
Apr 15, 2021Normal Progression of Bone Age with Chronological Age Over 60 Months with Vosoritide for Children with Achondroplasia
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) presented new and updated data at the 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting that demonstrates...
-
Apr 13, 2021
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
-
Mar 20, 2021Height Gain is Maintained in 2nd Year of Treatment
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg dose of vosoritide was presented at an oral...
-
Mar 8, 2021RMAT Designation Granted by FDA During Bleeding Disorders Awareness Month
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to valoctocogene...
-
Mar 3, 2021Topline data expected to be available in mid-2022
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment in a global Phase 2 randomized, placebo-controlled study of vosoritide, an...